Immuron Limited (AU:IMC) has released an update.
Immuron Limited reports robust sales growth for its gastrointestinal supplement Travelan, with a 13% increase globally in the September 2024 quarter, led by a significant 48% rise in North America and steady growth in Australia. The company continues to expand its market presence, securing additional pharmacy group partnerships in Australia and increasing distribution channels across North America and Canada.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
